No Data
No Data
Earnings Preview: NMRA to Report Financial Results Pre-market on March 03
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $4
Express News | Neumora Therapeutics Inc : Mizuho Cuts Target Price to $4 From $20
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Announces Target Price $4
Insider Sale: See Remarks of $NMRA Sells 1,978 Shares
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Neumora Therapeutics, Inc. (NMRA)
Mieshalan : Soon